Goodwill and Intangible Assets, Net (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of carrying value of goodwill

	March 31, 2021		December 31, 2020
Cell Therapy	$	112,347	$	112,347
Degenerative Disease		3,610		3,610
Biobanking		7,347		7,347
	$	123,304	$	123,304

	Cell Therapy		Degenerative Disease			Biobanking			Total
Balance at December 31, 2018	$	112,347	$	7,374		$	10,921		$	130,642
Adjustment(1)		—		—			(3,574	)		(3,574	)
Balance at December 31, 2019	$	112,347	$	7,374		$	7,347		$	127,068
Disposal of UltraMIST (Note 3)		—		(3,764	)		—			(3,764	)
Impairment		—		—			—			—
Balance at December 31, 2020	$	112,347	$	3,610		$	7,347		$	123,304

(1)      An adjustment was recorded to reflect a purchase price adjustment related to the fair value of contingent consideration.

Schedule of intangible assets net

	March 31, 2021			December 31, 2020			Estimated Useful Lives
Amortizable intangible assets:
Developed technology	$	16,810		$	16,810		11 – 16 years
Customer relationships		2,413			2,413		10 years
Trade names & trademarks		570			570		10 – 13 years
Reacquired rights		4,200			4,200		6 years
		23,993			23,993
Less: Accumulated amortization
Developed technology		(4,492	)		(4,203	)
Customer relationships		(971	)		(906	)
Trade names & trademarks		(178	)		(165	)
Reacquired rights		(2,013	)		(1,840	)
		(7,654	)		(7,114	)
Amortizable intangible assets, net		16,339			16,879
Non-amortized intangible assets
Acquired IPR&D product rights		108,500			108,500		indefinite
	$	124,839		$	125,379

	December 31, 2020			December 31, 2019			Estimated Useful Lives
Amortizable intangible assets:
Developed technology	$	16,810		$	16,810		11 – 16 years
Customer relationships		2,413			2,413		10 years
Trade names & trademarks		570			570		10 – 13 years
Reacquired rights		4,200			4,200		6 years
Composite assets		—			17,550		9 – 10 years
		23,993			41,543
Less: Accumulated amortization
Developed technology		(4,203	)		(3,030	)
Customer relationships		(906	)		(641	)
Trade names & trademarks		(165	)		(107	)
Reacquired rights		(1,840	)		(1,108	)
Composite assets		—			(3,088	)
		(7,114	)		(7,974	)
Amortizable intangible assets, net		16,879			33,569
Non-amortized intangible assets
Acquired IPR&D product rights		108,500			237,900		indefinite
	$	125,379		$	271,469

Schedule of five succeeding years related to intangible assets

2021	$	2,193
2022		2,193
2023		2,193
2024		1,784
2025		1,493